Biomea Fusion Announces Leadership Transition

Executive Leadership Change - Biomea Fusion, Inc. announced the appointment of Mick Hitchcock as interim CEO, replacing Thomas Butler, effective immediately [2][4] - Hitchcock has been a board member since 2021 and has extensive experience in pharmaceutical research and development [3] Clinical Development Progress - The company is focused on developing a novel therapy for diabetes, with recent positive Phase II data for icovamenib in insulin-deficient patients marking a significant milestone [3] - Biomea is advancing late-stage development efforts and preparing for regulatory engagement [3] Company Mission and Strategy - Biomea aims to cure diabetes through innovative covalent therapies, utilizing its proprietary FUSION™ System to develop next-generation small-molecule medicines [5][6] - The company emphasizes the advantages of covalent small molecules, including greater target selectivity and the potential for deeper, more durable responses [5]